Sugi Predict

Sugi Predict / Compounds / SCHEMBL3731709

SCHEMBL3731709

SCHEMBL3731709

CCC(OC(=O)[C@@H](N)C(C)C)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 2/20 0.46
▸ LAP3 P28838 2/20 0.38
▸ SLC1A3 P43003 3/20 0.34
▸ SLC1A2 P43004 3/20 0.34
▸ SLC1A1 P43005 3/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ SLC15A1 P46059 1/20 0.33
▸ KLK7 P49862 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ MMP1 P03956 1/20 0.32
▸ MMP2 P08253 1/20 0.32
▸ MMP3 P08254 1/20 0.32
▸ MMP9 P14780 1/20 0.32
▸ MMP13 P45452 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ USP2 O75604 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8119374 1.00 SLC7A5 (0.46) SLC7A5LAP3SLC1A3SLC1A2SLC1A1
SCHEMBL3735883 0.87 LAP3 (0.40) SLC7A5LAP3
SCHEMBL6027560 0.87 LAP3 (0.40) SLC7A5LAP3
SCHEMBL3735881 0.87 LAP3 (0.40) SLC7A5LAP3
SCHEMBL30284487 0.84 SLC1A3 (0.36) SLC7A5LAP3SLC1A3SLC1A2SLC1A1
SCHEMBL15323761 0.82 SLC7A5 (0.33) SLC7A5LAP3ACHE
Alanine SCHEMBL15322894 0.81 LAP3 (0.33) SLC7A5LAP3SLC1A3SLC1A2SLC1A1
SCHEMBL3737655 0.81 SLC7A5 (0.39) SLC7A5LAP3SLC1A3SLC1A2SLC1A1
SCHEMBL3737648 0.81 SLC7A5 (0.39) SLC7A5LAP3SLC1A3SLC1A2SLC1A1
SCHEMBL8124588 0.80 SLC15A1 (0.35) SLC7A5LAP3SLC15A1MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240156772-A1 PHARMACOKINETICS OF COMBINED RELEASE FORMULATIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE XWPharma Ltd. (KY) 2024-05-16 — — US claimed
EP-4225274-A1 MODIFIED RELEASE COMPOSITIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE XWPharma Ltd. (KY) 2023-08-16 — — EP claimed
WO-2022076466-A1 MODIFIED RELEASE COMPOSITIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE XWPharma Ltd. (KY) 2022-04-14 — — WO claimed
US-20220105044-A1 MODIFIED RELEASE COMPOSITIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE XWPharma Ltd. (KY) 2022-04-07 — — US claimed
CN-121941490-A Pharmaceutical composition of gamma-hydroxybutyric acid derivative 凯瑞康宁公司 2026-04-28 — — CN disclosed
CN-119970650-A Modified release compositions of gamma hydroxybutyric acid derivatives 凯瑞康宁生物工程有限公司 2025-05-13 — — CN disclosed
CN-115666527-B Modified release compositions of gamma hydroxybutyric acid derivatives 凯瑞康宁生物工程有限公司 2025-03-07 — — CN disclosed
CN-115666527-A Modified release compositions of gamma-hydroxybutyric acid derivatives 凯瑞康宁生物工程有限公司 2023-01-31 — — CN disclosed
US-7825238-B2 Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine MEDIVIR AB (SE) 2010-11-02 — — US disclosed
US-7071173-B2 Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine MEDIVIR AB (SE) 2006-07-04 — — US disclosed
US-20060122383-A1 Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine MEDIVIR AB (SE) 2006-06-08 — — US disclosed
US-20060058259-A1 ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE MEDIVIR AB (SE) 2006-03-16 — — US disclosed
US-20030186924-A1 Prodrugs MEDIVIR AB 2003-10-02 — — US disclosed
US-6458772-B1 Prodrugs MEDIVIR AB (SE) 2002-10-01 — — US disclosed
EP-1123935-A2 3'-Fluorinated guanosine derivatives for the treatment or prophylaxis of HBV or retroviral infections MEDIVIR AB (SE) 2001-08-16 — — EP disclosed
EP-0988304-B1 NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) MEDIVIR AB (SE) 2001-05-02 — — EP disclosed
EP-1054891-A1 PRODRUGS MEDIVIR AB (SE) 2000-11-29 — — EP disclosed
EP-0988304-A1 NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) MEDIVIR AB (SE) 2000-03-29 — — EP disclosed
WO-1999041275-A1 PRODRUGS MEDIVIR AB (SE) 1999-08-19 — — WO disclosed
WO-1999009031-A1 NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) MEDIVIR AB (SE) 1999-02-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058259-A1 ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE UNG, HAVCR2, EIF2AK2 SLC7A5 833/4885LAP3 1797/4885SLC1A3 2658/4885
US-20030186924-A1 Prodrugs HAVCR2, CYP7A1, IGSF11 SLC7A5 877/4885LAP3 1832/4885SLC1A3 2127/4885
US-20060122383-A1 Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine UNG, HAVCR2, EIF2AK2 SLC7A5 833/4885LAP3 1797/4885SLC1A3 2658/4885
US-20220105044-A1 MODIFIED RELEASE COMPOSITIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE GABRB3, GABBR1, GABRB1 SLC7A5 1047/4885LAP3 2291/4885SLC1A3 1314/4885
US-20240156772-A1 PHARMACOKINETICS OF COMBINED RELEASE FORMULATIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE GABRB3, GABRB1, GABRB2 SLC7A5 316/4885LAP3 1566/4885SLC1A3 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.